No abstract available
MeSH terms
-
Aged
-
Antineoplastic Agents / therapeutic use
-
Breast Neoplasms / complications*
-
Breast Neoplasms / therapy
-
Carrier Proteins / genetics*
-
Combined Modality Therapy
-
Drug Resistance, Neoplasm / drug effects
-
Erythroid Cells / drug effects
-
Erythroid Cells / metabolism
-
Erythroid Cells / pathology
-
Female
-
Granulocytes / drug effects
-
Granulocytes / metabolism
-
Granulocytes / pathology
-
Humans
-
Hydroxyurea / therapeutic use
-
In Vitro Techniques
-
Janus Kinase 2 / antagonists & inhibitors*
-
Leukemia, Neutrophilic, Chronic / drug therapy
-
Leukemia, Neutrophilic, Chronic / etiology*
-
Leukemia, Neutrophilic, Chronic / pathology
-
Mutation / genetics*
-
Nitriles
-
Nuclear Proteins / genetics*
-
Prognosis
-
Pyrazoles / therapeutic use*
-
Pyrimidines
-
Receptors, Colony-Stimulating Factor / genetics*
-
Tumor Cells, Cultured
Substances
-
Antineoplastic Agents
-
CSF3R protein, human
-
Carrier Proteins
-
Nitriles
-
Nuclear Proteins
-
Pyrazoles
-
Pyrimidines
-
Receptors, Colony-Stimulating Factor
-
SETBP1 protein, human
-
ruxolitinib
-
JAK2 protein, human
-
Janus Kinase 2
-
Hydroxyurea